The stock price of Viridian Therapeutics Inc (NASDAQ: VRDN) has plunged by -2.22 when compared to previous closing price of 20.24, but the company has seen a -11.97% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-12 that Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.
Is It Worth Investing in Viridian Therapeutics Inc (NASDAQ: VRDN) Right Now?
VRDN has 36-month beta value of 1.07. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 7 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRDN is 70.14M, and currently, short sellers hold a 14.29% ratio of that float. The average trading volume of VRDN on November 21, 2024 was 1.50M shares.
VRDN’s Market Performance
The stock of Viridian Therapeutics Inc (VRDN) has seen a -11.97% decrease in the past week, with a -19.03% drop in the past month, and a 29.01% gain in the past quarter. The volatility ratio for the week is 6.31%, and the volatility levels for the past 30 days are at 5.62% for VRDN. The simple moving average for the last 20 days is -12.34% for VRDN stock, with a simple moving average of 15.17% for the last 200 days.
Analysts’ Opinion of VRDN
Many brokerage firms have already submitted their reports for VRDN stocks, with Needham repeating the rating for VRDN by listing it as a “Buy.” The predicted price for VRDN in the upcoming period, according to Needham is $38 based on the research report published on September 11, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see VRDN reach a price target of $29. The rating they have provided for VRDN stocks is “Outperform” according to the report published on June 11th, 2024.
Goldman gave a rating of “Buy” to VRDN, setting the target price at $23 in the report published on June 06th of the current year.
VRDN Trading at -13.16% from the 50-Day Moving Average
After a stumble in the market that brought VRDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.24% of loss for the given period.
Volatility was left at 5.62%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares sank -15.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.05% lower at present.
During the last 5 trading sessions, VRDN fell by -11.97%, which changed the moving average for the period of 200-days by +7.03% in comparison to the 20-day moving average, which settled at $22.58. In addition, Viridian Therapeutics Inc saw -9.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRDN starting from Beetham Thomas W., who purchase 5,000 shares at the price of $23.41 back on Sep 27 ’24. After this action, Beetham Thomas W. now owns 6,000 shares of Viridian Therapeutics Inc, valued at $117,050 using the latest closing price.
Mahoney Stephen F., the President and CEO of Viridian Therapeutics Inc, purchase 21,400 shares at $23.33 during a trade that took place back on Sep 27 ’24, which means that Mahoney Stephen F. is holding 21,400 shares at $499,262 based on the most recent closing price.
Stock Fundamentals for VRDN
Current profitability levels for the company are sitting at:
- -937.23 for the present operating margin
- -20.48 for the gross margin
The net margin for Viridian Therapeutics Inc stands at -851.27. The total capital return value is set at -0.39. Equity return is now at value -51.88, with -46.71 for asset returns.
Based on Viridian Therapeutics Inc (VRDN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -9.6. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -91.19.
Currently, EBITDA for the company is -234.56 million with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 4597.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.55.
Conclusion
To put it simply, Viridian Therapeutics Inc (VRDN) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
